American Journal of Kidney Diseases
Volume 51, Issue 1 , Pages 62-70 , January 2008

Exploring Relative Mortality and Epoetin Alfa Dose Among Hemodialysis Patients

  • Brian D. Bradbury, DSc

      Affiliations

    • Department of Biostatistics & Epidemiology, Amgen Inc, Thousand Oaks, CA
    • Corresponding Author InformationAddress correspondence to Brian D. Bradbury, DSc, Department of Biostatistics & Epidemiology, Amgen Inc, Thousand Oaks, CA 91320.
    • ,
  • Ouhong Wang, PhD

      Affiliations

    • Department of Biostatistics & Epidemiology, Amgen Inc, Thousand Oaks, CA
    • ,
  • Cathy W. Critchlow, PhD

      Affiliations

    • Department of Biostatistics & Epidemiology, Amgen Inc, Thousand Oaks, CA
    • ,
  • Kenneth J. Rothman, DrPH

      Affiliations

    • Department of Epidemiology, Boston University, Boston, MA
    • Research Triangle Institute Int, Research Triangle Park, NC
    • ,
  • Patrick Heagerty, PhD

      Affiliations

    • Department of Biostatistics, University of Washington, Seattle, WA.
    • ,
  • Marcia Keen, PhD

      Affiliations

    • Department of Biostatistics & Epidemiology, Amgen Inc, Thousand Oaks, CA
    • ,
  • John F. Acquavella, PhD

      Affiliations

    • Department of Biostatistics & Epidemiology, Amgen Inc, Thousand Oaks, CA

Received 20 February 2007 ,Accepted 5 September 2007.

References 

  1. Cotter DJ, Stefanik K, Zhang Y, Thamer M, Scharfstein D, Kaufman J. Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients. J Clin Epidemiol. 2004;57:1086–1095
  2. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis. 2004;44:866–876
  3. US Renal Data System. USRDS 2004 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2005;
  4. Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: Associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol. 2006;1:1205–1210
  5. Leavey SF, Strawderman RL, Jones CA, Port FK, Held PJ. Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. Am J Kidney Dis. 1998;31:997–1006
  6. Fernandez-Reyes MJ, Alvarez-Ude F, Sanchez R, et al. Inflammation and malnutrition as predictors of mortality in patients on hemodialysis. J Nephrol. 2002;15:136–143
  7. Cooper BA, Penne EL, Bartlett LH, Pollock CA. Protein malnutrition and hypoalbuminemia as predictors of vascular events and mortality in ESRD. Am J Kidney Dis. 2004;43:61–66
  8. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005;67:1179–1187
  9. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–2218
  10. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70:771–780
  11. Astor BC, Eustace JA, Powe NR, Klag MJ, Fink NE, Coresh J. Type of vascular access and survival among incident hemodialysis patients: The Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study. J Am Soc Nephrol. 2005;16:1449–1455
  12. Bradbury BD, Fissell RB, Albert JM, et al. Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol. 2007;2:89–99
  13. Goldwasser P, Mittman N, Antignani A, et al. Predictors of mortality in hemodialysis patients. J Am Soc Nephrol. 1993;3:1613–1622
  14. den Elzen WP, van Manen JG, Boeschoten EW, Krediet RT, Dekker FW. The effect of single and repeatedly high concentrations of C-reactive protein on cardiovascular and non-cardiovascular mortality in patients starting with dialysis. Nephrol Dial Transplant. 2006;21:1588–1595
  15. Honda H, Qureshi AR, Heimburger O, et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis. 2006;47:139–148
  16. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol. 1999;10:610–619
  17. Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int. 2003;63:1908–1914
  18. Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44:94–111
  19. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006;17:1181–1191
  20. Robinson BM, Joffe MM, Berns JS, Pisoni RL, Port FK, Feldman HI. Anemia and mortality in hemodialysis patients: Accounting for morbidity and treatment variables updated over time. Kidney Int. 2005;68:2323–2330
  21. Roberts TL, Obrador GT, St Peter WL, Pereira BJ, Collins AJ. Relationship among catheter insertions, vascular access infections, and anemia management in hemodialysis patients. Kidney Int. 2004;66:2429–2436
  22. Kausz AT, Solid C, Pereira BJ, Collins AJ, St Peter W. Intractable anemia among hemodialysis patients: A sign of suboptimal management or a marker of disease?. Am J Kidney Dis. 2005;45:136–147
  23. Teruel JL, Marcen R, Ocana J, et al. Clinical significance of C-reactive protein in patients on hemodialysis: A longitudinal study. Nephron Clin Pract. 2005;100:c140–c145
  24. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol. 1989;129:125–137
  25. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11:561–570
  26. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11:550–560
  27. Robins JM, Blevins D, Ritter G, Wulfsohn M. G-estimation of the effect of prophylaxis therapy for Pneumocystis carinii pneumonia on the survival of AIDS patients. Epidemiology. 1992;3:319–336
  28. Brookhart MA, Wang PS, Solomon DH, Schneeweiss S. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology. 2006;17:268–275

 Originally published online as doi:10.1053/j.ajkd.2007.09.015 on November 30, 2007.

PII: S0272-6386(07)01351-0

doi: 10.1053/j.ajkd.2007.09.015

American Journal of Kidney Diseases
Volume 51, Issue 1 , Pages 62-70 , January 2008

Article Tools

* Image Usage & Resolution